RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis
Ponce Aix, S, Novello, S, Garon, EB, Nakagawa, K, Nadal, E, Moro-Sibilot, D, Alonso Garcia, M, Fabre, E, Frimodt-Moller, B, Zimmermann, AH, Visseren-Grul, CM, Reck, M
Published in Cancer treatment and research communications (2021)
Published in Cancer treatment and research communications (2021)
Get full text
Journal Article
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
Lisberg, A., Cummings, A., Goldman, J.W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., Wolf, B., Jones, B., Madrigal, J., Horton, J., Spiegel, M., Carroll, J., Gukasyan, J., Williams, T., Sauer, L., Wells, C., Hardy, A., Linares, P., Lim, C., Ma, L., Adame, C., Garon, Edward B.
Published in Journal of thoracic oncology (01.08.2018)
Published in Journal of thoracic oncology (01.08.2018)
Get full text
Journal Article
A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
Garon, Edward B, Neidhart, Jeffrey D, Gabrail, Nashat Y, de Oliveira, Moacyr R, Balkissoon, Jai, Kabbinavar, Fairooz
Published in OncoTargets and therapy (2016)
Published in OncoTargets and therapy (2016)
Get full text
Journal Article
Update REVEL: Eine randomisierte, doppelblinde Phase III Studie von Docetaxel (DOC) und Ramucirumab (RAM; IMC-1121B) versus DOC und Placebo (PL) in der Zweitlinienbehandlung des Nicht-Kleinzelligen Lungenkarzinoms im Stadium IV nach Progression der Erkrankung nach einer Platin-basierten Vortherapie
Reck, M, Thomas, M, Schuette, W, Kimmich, M, Rittmeyer, A, Heinrich, B, Yurasov, S, Zimmermann, A, Carter, GC, Garon, EB, Pérol, M
Published in Pneumologie (04.02.2015)
Published in Pneumologie (04.02.2015)
Get full text
Conference Proceeding